Hepatic encephalopathy (ammonia)
Hepatic encephalopathy (HE) is a neuropsychiatric complication of cirrhosis driven largely by gut-derived ammonia: urease-producing gut flora (Streptococcus, Klebsiella, Proteus, Enterococcus, and related pathobionts) hydrolyze urea into ammonia, which a failing liver cannot clear, allowing it to cross the blood-brain barrier and cause confusion, asterixis, and coma. Current mainstays (lactulose and the poorly-absorbed antibiotic rifaximin) are non-specific, broadly suppress the microbiome, and are limited by tolerability and emerging resistance concerns. Bacteriophages are attractive here precisely because the offending trait is carried by identifiable, often expandable bacterial clades: phages can be selected to lyse specific urease-rich strains while sparing the beneficial, ammonia-neutral commensals that non-specific antibiotics also kill. This strain-level precision, plus the self-amplifying, gut-restricted nature of orally delivered phages, makes them a conceptually clean tool for lowering the ammonia-generating bacterial load at its source.
How phages act here
Mechanism
Phages act by binding strain-specific surface receptors and lysing only their host bacteria, so a rationally assembled cocktail can deplete urease-positive, ammonia-generating taxa (e.g., urease-rich Streptococcus, Klebsiella, Proteus, or cytolytic Enterococcus) while leaving the rest of the community intact — directly shrinking the metabolic capacity that converts urea to ammonia, rather than inhibiting the urease enzyme pharmacologically. Cocktails combine multiple phages with complementary host ranges to broaden coverage across the heterogeneous urease-producing flora seen in cirrhosis and to suppress resistance, and phage depolymerases can degrade the capsular polysaccharide and biofilm matrix that protect gut pathobionts such as Klebsiella. Beyond natural isolates, engineered and CRISPR-armed phages are being explored to deliver sequence-specific kill switches against defined virulence or metabolic genes, in principle allowing targeting of the urease operon itself or of cytolysin-type toxin genes. Phages can also be paired with existing agents (e.g., rifaximin) for additive or synergistic microbiome editing, an approach analogous to phage-antibiotic synergy demonstrated in other infections.
Where it stands
Current evidence
As of 2026 this is a mechanistically grounded but pre-clinical indication: there is no completed (or, to public registries, registered) human trial of a phage cocktail specifically for hepatic encephalopathy. The two anchoring pieces of evidence are (1) Bajaj et al., Gut 2021, which sequenced the bacterial metagenome and virome of cirrhotic patients and found that phage-bacterial linkages centered on urease-producing, ammonia-generating Streptococcus species shifted with HE severity and collapsed after rifaximin — establishing that phages already co-regulate the exact urease-producing flora implicated in HE; and (2) Duan et al., Nature 2019, the landmark proof-of-concept showing that a precision phage cocktail isolated against cytolysin-producing Enterococcus faecalis abolished ethanol-induced liver disease in humanized mice, while phages against non-cytolytic strains did not — demonstrating that an orally delivered, strain-specific phage cocktail can edit a gut pathobiont and reverse liver injury. Supporting virome work (Peña Rodríguez/Bajaj, Clin Transl Gastroenterol 2024) further ties specific gut phage signatures to HE and hospitalization outcomes. In parallel, the broader field is validating the target itself — e.g., gut-bacterial urease inhibitors that lower ammonemia in rodent models of liver injury (Nature Communications 2024) and engineered ammonia-consuming probiotics (Synlogic SYNB1020, which reached an early human study) — but the phage-cocktail-for-HE concept remains at the bench-to-translational interface, awaiting first-in-human evaluation.
Evidence confidence: low
The data
Key studies & trials
- Bajaj JS, Sikaroodi M, Shamsaddini A, Fagan A, Sterling RK, Gavis E, Khoruts A, Fodor AA, Gillevet PM. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. Gut. 2021 Jun;70(6):1162-1173. ↗
- Duan Y, Llorente C, Lang S, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019 Nov;575(7783):505-511. ↗
- Peña Rodríguez M, Fagan A, Sikaroodi M, Gillevet PM, Bajaj JS. Proton Pump Inhibitor Use and Complications of Cirrhosis Are Linked With Distinct Gut Microbial Bacteriophage and Eukaryotic Viral-Like Particle Signatures in Cirrhosis. Clin Transl Gastroenterol. 2024 Feb 1;15(2):e00659. ↗
- Konieczna I, et al. (work on gut bacterial urease inhibition lowering ammonemia) — Maroni L, et al. Inhibition of urease-mediated ammonia production by 2-octynohydroxamic acid in hepatic encephalopathy. Nat Commun. 2024 Mar 12;15(1):2306. ↗
Who is working on it
Programs & centers
The possibility
Picture a future where a cirrhotic patient's stool is sequenced, their personal roster of urease-rich ammonia factories is identified, and a matched phage cocktail is delivered as a simple oral capsule that hunts those exact strains through the gut while leaving the protective microbiome untouched — lowering blood ammonia without the diarrhea of lactulose or the resistance pressure of chronic antibiotics. CRISPR-armed and depolymerase-equipped phages could push this further, dismantling Klebsiella biofilms or silencing the urease operon itself, and self-amplifying with each round of bacterial killing so a small dose does outsized work. If the precision that abolished alcoholic liver disease in humanized mice can be redirected at the urease-producing flora behind HE, phage cocktails could become the first truly strain-targeted way to keep the brain clear in advanced liver disease.